Down 20.80%: 4586.T MedRx Co., Ltd (JPX) falls to JPY 99.00, what investors watch

MedRx Co., Ltd (4586.T) plunged 20.80% to JPY 99.00 at the JPX close on 09 Mar 2026, marking one of the day’s largest drops among healthcare names. The move followed heavy selling volume of 3,034,400.00 shares versus an average of 945,189.00, and left the stock well below its 50-day average of JPY 111.72. This market-closed decline highlights rising investor concern about pipeline timing and negative earnings metrics, and it sets a more cautious near-term outlook for 4586.T stock across trading desks and analysts.

Price action and trading stats for 4586.T stock

At market close on 09 Mar 2026 the reported price is JPY 99.00, down JPY 26.00 from the previous close of JPY 125.00, a 20.80% decline. Intraday range was JPY 97.00–JPY 102.00 and volume hit 3,034,400.00, a relative volume of 16.66, signalling outsized flows. Year high stands at JPY 225.00 and year low at JPY 55.00, showing wide volatility. Traders will watch the 50-day average JPY 111.72 and 200-day average JPY 103.18 as near resistance levels for any short-covering rebound.

Fundamentals and valuation: what 4586.T stock shows

MedRx reports negative earnings with EPS -13.36 and a trailing PE of -8.01, reflecting current losses. Price-to-sales is elevated at 49.59 while price-to-book is 3.37, and cash per share is JPY 27.18. The company’s current ratio is strong at 23.62, which indicates liquidity but also low operating cash flows (operating cash flow per share 0.00). These ratios explain why valuation looks stretched for 4586.T stock despite a cash buffer.

Clinical pipeline and news drivers affecting 4586.T stock

MedRx’s pipeline includes MRX-4TZT and MRX-9FLT in phase I and several pre-clinical programs targeting pain and Alzheimer’s disease. Clinical milestones or setback headlines tend to swing the stock sharply. There was no formal company announcement today, so the sell-off reflects sector rotation and risk-off positioning in small-cap pharma. For local market context see recent Japan healthcare moves Nikkei Market News.

Technical view and short-term outlook for 4586.T stock

Technicals show neutral-to-bearish momentum: RSI 49.41 and MACD histogram 1.20 with ADX 26.01 indicating a strong trend. Bollinger Bands centre at JPY 106.05 and lower band JPY 91.01; the current close near JPY 99.00 sits between support and resistance. OBV is negative and ATR 7.24 points to higher intraday volatility. Short-term traders should watch JPY 91.00 support and the JPY 106.00–112.00 resistance zone.

Meyka AI grading and analyst consensus on 4586.T stock

Meyka AI rates 4586.T with a score out of 100: the model assigns a score 69.74 (Grade B) with a suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Independent analyst ratings are limited; third-party composite in our feed flags a company rating of D+ / Strong Sell dated 06 Mar 2026, reflecting valuation and profitability weaknesses.

Forecasts and price targets for 4586.T stock

Meyka AI’s forecast model projects a short-term monthly level JPY 97.40, a quarterly target JPY 82.65, and a 12-month base-case JPY 53.07. Compared with the current price JPY 99.00, the 12-month model implies downside of -46.38%. A recovery scenario near the 50-day average would place a technical target around JPY 111.72. Forecasts are model-based projections and not guarantees. Internal coverage and updates are available on the Meyka stock page Meyka 4586.T and broader market context via Reuters Japan markets.

Final Thoughts

MedRx Co., Ltd (4586.T) finished the JPX session on 09 Mar 2026 at JPY 99.00, down 20.80% on heavy volume, and underperformed the broader healthcare group which was modestly positive today. The immediate drivers appear technical and liquidity-driven rather than fresh company disclosures, but the stock’s weak profitability (EPS -13.36, PE negative) and high price-to-sales (49.59) keep fundamental risk elevated. Meyka AI’s forecast model projects a 12-month base-case of JPY 53.07, implying -46.38% from the close; the monthly projection is JPY 97.40, closer to current levels. Our in-house grade (Meyka AI rates 4586.T with a score out of 100: 69.74, Grade B, HOLD) reflects mixed signals — healthy cash buffers and pipeline progress against stretched valuation and operating losses. For investors, the trade is clear: risk-managed exposure only, use tight stops, and watch clinical updates or capital moves that could change the risk profile. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.